Roche Diagnostics GmbH

Germany

Back to Profile
1-2 of 2 for Roche Diagnostics GmbH Sort by
Query
Patent
United States - USPTO
Aggregations Reset Report
Date
2021 1
Before 2019 1
IPC Class
A01K 67/00 - Rearing or breeding animals, not otherwise provided for; New breeds of animals 1
A01K 67/027 - New breeds of vertebrates 1
A61K 39/00 - Medicinal preparations containing antigens or antibodies 1
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical 1
C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants 1
See more
Status
Pending 1
Registered / In Force 1
Found results for  patents

1.

THYMIDINE KINASE (TK-1) IN PROGNOSTIC INDICES FOR DLBCL

      
Application Number 17186163
Status Pending
Filing Date 2021-02-26
First Publication Date 2021-07-01
Owner
  • F. HOFFMANN-LA ROCHE AG (Switzerland)
  • ROCHE DIAGNOSTICS GMBH (Germany)
Inventor
  • Rolny, Vinzent
  • Rutz, Sandra
  • Morgenstern, David
  • Pinchuk, Boris
  • Zimmermann, Christina
  • Klammer, Martin
  • Sonner, Franziska

Abstract

The present disclosure relates to the finding that thymidine kinase 1 (TK-1) represents a valuable biomarker in a method for determining a Prognostic Index (PI) for risk stratification of a patient with aggressive B-cell lymphoma, especially diffuse large B-cell lymphoma (DLBCL), to the use of TK-1 in such PI and to a PI comprising the marker TK-1.

IPC Classes  ?

  • G01N 33/573 - Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
  • G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

2.

Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals

      
Application Number 12972290
Grant Number 09476027
Status In Force
Filing Date 2010-12-17
First Publication Date 2011-04-21
Grant Date 2016-10-25
Owner Roche Diagnostics GMBH (Germany)
Inventor Buelow, Roland

Abstract

The present invention describes transgenic animals with human(ized) immunoglobulin loci and transgenes encoding human(ized) Igα and/or Igβ sequences. Of particular interest are animals with transgenic heavy and light chain immunoglobulin loci capable of producing a diversified human(ized) antibody repertoire that have their endogenous production of Ig and/or endogenous Igα and/or Igβ sequences suppressed. Simultaneous expression of human(ized) immunoglobulin and human(ized) Igα and/or Igβ results in normal B-cell development, affinity maturation and efficient expression of human(ized) antibodies.

IPC Classes  ?

  • A01K 67/00 - Rearing or breeding animals, not otherwise provided for; New breeds of animals
  • A01K 67/027 - New breeds of vertebrates
  • C12N 15/00 - Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
  • C12N 5/0781 - B cells; Progenitors thereof
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
  • C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa
  • C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts